Applied DNA Sciences (NASDAQ:APDN) Second Quarter 2024 Results

Key Financial Results

• Revenue: US$929.6k (down 79% from 2Q 2023).
• Net loss: US$4.63m (down from US$588.3k profit in 2Q 2023).
• US$5.31 loss per share (down from US$0.91 profit in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Applied DNA Sciences Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 18%.

Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 8.0% from a week ago.

Risk Analysis

It is worth noting though that we have found 6 warning signs for Applied DNA Sciences (3 shouldn't be ignored!) that you need to take into consideration.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.